To whom it may concern:

April 1, 2025

Company name: ExaWizards Inc.
Name of representative: Makoto Haruta,
Representative Director and President
(TSE Code No.4259)
Inquiries: Tomoaki Maekawa,
Executive Officer Corporate Management
Head of Function

Notice on Subsidiary, ExaMD obtained the Type II Medical Device Manufacturing and Marketing License, and the Medical Device Sales License

ExaWizards Inc. (hereinafter, "the Company") announces that its subsidiary, ExaMD Inc. (hereinafter "ExaMD"), has obtained the Type II Medical Device Manufacturing and Marketing License, and the Medical Device Sales License from the Tokyo Metropolitan Government on March 31, 2025.

1. Overview

ExaMD is a company established in February 2024 with the purpose of providing AI services specialized in the health and medical fields. They develop and sell AI-powered medical devices and healthcare services, such as AI medical devices that diagnose dementia through conversational voice. ExaMD is 100% funded by ExaWizards Inc., an AI development company.

Currently, they are developing an ML-SaMD* that uses AI to determine whether a person has dementia through a short, one-minute free conversation using a smartphone. In February 2025, this product was designated as a priority review item by the Ministry of Health, Labour and Welfare.

With ExaMD's recent acquisition of licenses for Type II medical device manufacturing, marketing, and sales, they have established a system that allows for efficient execution of SaMD development, manufacturing, and sales independently. Moving forward, they aim to leverage these licenses and the priority review designation to achieve earlier approval.

Note: *ML-SaMD: Machine Learning-based Software as a Medical Device

Type II Medical Device Manufacturing and Marketing License: License# 13B2X10629

2. Impact to Consolidated Results

The Company is currently conducting a detailed analysis of the impact on future business development and performance. The Company will promptly disclose any significant impact as soon as it becomes known.